Biofutur

About Biofutur

In 1989, a story in French medical biology began with a single laboratory founded by Dr. Jacques Ravenau. This initial venture laid the groundwork for what would become Biofutur. The company's trajectory shifted in 2005 when Dr. Christophe Crouzier took over as president, steering the group's growth. Biofutur established itself as a key player in the Île-de-France region, operating a network of medical analysis laboratories managed by independent medical biologists. The business centered on providing a comprehensive range of local medical biology services, from routine tests to specialized diagnostics. By 2020, the group had grown significantly, representing 51 laboratories and serving over 6,000 patients daily, supported by a model that included two central technical platforms. That same year, the private equity firm Omnes Capital invested in Biofutur, aiming to accelerate its development and structure its activities for further growth. A pivotal chapter for Biofutur unfolded in late 2021 and early 2022. Inovie, a major French medical diagnostics group, entered into exclusive negotiations and subsequently acquired Biofutur. This was a significant event, marking Inovie's largest acquisition in 2021 and a strategic move to solidify its presence in the Greater Paris area. For Biofutur, joining the Inovie group offered a path to continue its development strategy within a larger, national structure, integrating its network of laboratories and expertise into a leading name in French medical biology.